Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women

Lung Cancer

Volumn 71, Issue 3, 2011, Pages 258-263

  Paulus, Jessica K ^a   Zhou, Wei ^a   Kraft, Peter ^a   Johnson, Bruce E ^b   Lin, Xihong ^a   Christiani, David C ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Estrogen receptor beta (ESR2); Molecular epidemiology; Non small cell lung cancer; Parity; Tobacco; Women

Indexed keywords

ESTROGEN RECEPTOR BETA;

ADULT; ALGORITHM; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARITY; PRIORITY JOURNAL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; WOMEN'S HEALTH;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; ESTROGEN RECEPTOR BETA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 79851510351     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.06.011     Document Type: Article

References (53)

1. American Cancer Society Cancer facts and figures 2008 2008, American Cancer Society, Atlanta.
2. Schwartz A.G., Yang P., Swanson G.M. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996, 144:554-562.
3. Osann K.E., nton-Culver H., Kurosaki T., Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993, 54:44-48.
4. Kreuzer M., Boffetta P., Whitley E., Ahrens W., Gaborieau V., Heinrich J., et al. Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer 2000, 82:227-233.
5. Thun M.J., Lally C.A., Flannery J.T., Calle E.E., Flanders W.D., Heath C.W. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997, 89:1580-1586.
6. Radzikowska E., Glaz P., Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002, 13:1087-1093.
7. Risch H.A., Howe G.R., Jain M., Burch J.D., Holowaty E.J., Miller A.B. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993, 138:281-293.
8. Cheng Y.W., Hsieh L.L., Lin P.P., Chen C.P., Chen C.Y., Lin T.S., et al. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen 2001, 37:304-310.
9. Harris R.E., Zang E.A., Anderson J.I., Wynder E.L. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol 1993, 22:592-599.
10. Henschke C.I., Yip R., Miettinen O.S. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 2006, 296:180-184.
11. Bain C., Feskanich D., Speizer F.E., Thun M., Hertzmark E., Rosner B.A., et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004, 96:826-834.
12. Bach P.B., Kattan M.W., Thornquist M.D., Kris M.G., Tate R.C., Barnett M.J., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003, 95:470-478.
13. Halpern M.T., Gillespie B.W., Warner K.E. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993, 85:457-464.
14. Freedman N.D., Leitzmann M.F., Hollenbeck A.R., Schatzkin A., Abnet C.C. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008, 9:649-656.
15. Kuiper G.G., Gustafsson J.A. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 1997, 410:87-90.
16. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93:5925-5930.
17. Schwartz A.G., Prysak G.M., Murphy V., Lonardo F., Pass H., Schwartz J., et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005, 11:7280-7287.
18. Omoto Y., Kobayashi Y., Nishida K., Tsuchiya E., Eguchi H., Nakagawa K., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001, 285:340-347.
19. Fasco M.J., Hurteau G.J., Spivack S.D. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002, 188:125-140.
20. Mollerup S., Jorgensen K., Berge G., Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37:153-159.
21. Wu C.T., Chang Y.L., Shih J.Y., Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005, 130:979-986.
22. Kaiser U., Hofmann J., Schilli M., Wegmann B., Klotz U., Wedel S., et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996, 67:357-364.
23. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65:1459-1470.
24. Hershberger P.A., Vasquez A.C., Kanterewicz B., Land S., Siegfried J.M., Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005, 65:1598-1605.
25. Schwartz A.G., Wenzlaff A.S., Prysak G.M., Murphy V., Cote M.L., Brooks S.C., et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007, 25:5785-5792.
26. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
27. Garcia-Closas M., Kelsey K.T., Wiencke J.K., Xu X., Wain J.C., Christiani D.C. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Causes Control 1997, 8:544-553.
28. Miller D.P., Neuberg D., De V.I., Wain J.C., Lynch T.J., Su L., et al. Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms. Epidemiology 2003, 14:545-551.
29. Ferris B.G. Epidemiology standardization project (American Thoracic Society). Am Rev Respir Dis 1978, 118:1-120.
30. Hunter D.J., Riboli E., Haiman C.A., Albanes D., Altshuler D., Chanock S.J., et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005, 5:977-985.
31. Chen Y.C., Kraft P., Bretsky P., Ketkar S., Hunter D.J., Albanes D., et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2007, 16:1973-1981.
32. Kolonel L.N., Henderson B.E., Hankin J.H., Nomura A.M., Wilkens L.R., Pike M.C., et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000, 151:346-357.
33. Stram D.O., Leigh P.C., Bretsky P., Freedman M., Hirschhorn J.N., Altshuler D., et al. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003, 55:179-190.
34. Cox D.G., Bretsky P., Kraft P., Pharoah P., Albanes D., Altshuler D., et al. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer 2008, 122:387-392.
35. Thurston S.W., Liu G., Miller D.P., Christiani D.C. Modeling lung cancer risk in case-control studies using a new dose metric of smoking. Cancer Epidemiol Biomarkers Prev 2005, 14:2296-2302.
36. Zaykin D.V., Westfall P.H., Young S.S., Karnoub M.A., Wagner M.J., Ehm M.G. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002, 53:79-91.
37. Schaid D.J. General score tests for associations of genetic markers with disease using cases and their parents. Genet Epidemiol 1996, 13:423-449.
38. Kraft P., Cox D.G., Paynter R.A., Hunter D., De V.I. Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 2005, 28:261-272.
39. Nichols H.B., Trentham-Dietz A., Hampton J.M., Titus-Ernstoff L., Egan K.M., Willett W.C., et al. From menarche to menopause: trends among US Women born from 1912 to 1969. Am J Epidemiol 2006, 164:1003-1011.
40. Paulus J.K., Asomaning K., Kraft P., Johnson B.E., Lin X., Christiani D.C. Parity and risk of lung cancer in women. Am J Epidemiol 2010, 171:557-563.
41. Kaiser U., Hofmann J., Schilli M., Wegmann B., Klotz U., Wedel S., et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer. 1996, 67:357-364.
42. Wu C.T., Chang Y.L., Lee Y.C. Expression of the estrogen receptor beta in 37 surgically treated pulmonary sclerosing hemangiomas in comparison with non-small cell lung carcinomas. Hum Pathol 2005, 36:1108-1112.
43. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
44. Taioli E., Wynder E.L. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994, 86:869-870.
45. Kreuzer M., Gerken M., Heinrich J., Kreienbrock L., Wichmann H.E. Hormonal factors and risk of lung cancer among women?. Int J Epidemiol 2003, 32:263-271.
46. Schabath M.B., Wu X., Vassilopoulou-Sellin R., Vaporciyan A.A., Spitz M.R. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004, 10:113-123.
47. Liu Y., Inoue M., Sobue T., Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 2005, 117:662-666.
48. Wu A.H., Yu M.C., Thomas D.C., Pike M.C., Henderson B.E. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988, 48:7279-7284.
49. Adami H.O., Persson I., Hoover R., Schairer C., Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989, 44:833-839.
50. Olsson H., Bladstrom A., Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy?. Obstet Gynecol 2003, 102:565-570.
51. Rodriguez C., Spencer F.H., Deka A., Patel A.V., Jacobs E.J., Thun M.J., et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2008, 17:655-660.
52. Elliott A.M., Hannaford P.C. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2006, 73:331-335.
53. Blackman J.A., Coogan P.F., Rosenberg L., Strom B.L., Zauber A.G., Palmer J.R., et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 2002, 11:561-567.